Villanova Investment Management Co LLC Buys 46,294 Shares of InMode Ltd. $INMD

Villanova Investment Management Co LLC raised its stake in shares of InMode Ltd. (NASDAQ:INMD) by 164.4% during the 2nd quarter, Holdings Channel.com reports. The fund owned 74,456 shares of the healthcare company’s stock after acquiring an additional 46,294 shares during the period. Villanova Investment Management Co LLC’s holdings in InMode were worth $1,075,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of INMD. Jump Financial LLC purchased a new stake in shares of InMode in the second quarter valued at about $3,852,000. Marshall Wace LLP boosted its holdings in InMode by 270.7% during the second quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock worth $8,022,000 after purchasing an additional 405,707 shares during the last quarter. Systematic Financial Management LP grew its position in InMode by 3.9% in the 2nd quarter. Systematic Financial Management LP now owns 1,090,971 shares of the healthcare company’s stock worth $15,754,000 after purchasing an additional 41,363 shares in the last quarter. Quantbot Technologies LP increased its stake in InMode by 120.7% in the 2nd quarter. Quantbot Technologies LP now owns 181,764 shares of the healthcare company’s stock valued at $2,625,000 after buying an additional 99,410 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp lifted its position in shares of InMode by 55.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 200,043 shares of the healthcare company’s stock worth $2,889,000 after buying an additional 71,231 shares in the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Friday, October 10th. Wall Street Zen cut InMode from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a research note on Wednesday, October 8th. UBS Group decreased their target price on InMode from $16.25 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Finally, Zacks Research raised shares of InMode from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $16.80.

InMode Price Performance

NASDAQ:INMD opened at $14.42 on Monday. The company has a market capitalization of $911.49 million, a P/E ratio of 6.68 and a beta of 2.14. The business has a fifty day simple moving average of $14.79 and a two-hundred day simple moving average of $14.58. InMode Ltd. has a 1 year low of $13.14 and a 1 year high of $19.78.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.